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 ABSTRACT 
Current approaches for the treatment of chronic lymphocytic leukemia (CLL) have
greatly improved the prognosis for survival, but some patients remain refractive to
these therapeutic regimens. Hence, in addition to reducing the long-term side-
effects of therapeutics for all leukemia patients, there is an urgent need for novel 
therapeutic strategies for difficult-to-treat leukemia cases. Due to the cytotoxicity
of drugs, the major challenge currently is to deliver the therapeutic agents to 
neoplastic cells while preserving the viability of non-malignant cells. In this study,
we propose a therapeutic approach in which high doses of hydroxychloroquine 
and chlorambucil were loaded into biodegradable polymeric nanoparticles coated 
with an anti-CD20 antibody.We first demonstrated the ability of the nanoparticles 
to target and internalize in tumor B-cells. Moreover, these nanoparticles could kill
not only p53-mutated/deleted leukemia cells expressing a low amount of CD20, but
also circulating primary cells isolated from chronic lymphocytic leukemia patients.
The safety of these nanoparticles was also demonstrated in healthy mice, and 
their therapeutic effects were shown in a new model of aggressive leukemia. These 
results showed that anti-CD20 nanoparticles containing hydroxychloroquine and 
chlorambucil can be effective in controlling aggressive leukemia and provided a
rationale for adopting this approach for the treatment of other B-cell disorders.
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1 Introduction 
Chronic lymphocytic leukemia (CLL) is a hetero-
geneous disease with highly variable clinical courses 
and survivals ranging from months to decades. In 
particular, a subset of patients is affected by a high- 
risk CLL form that rapidly progresses and develops 
into a disease that requires symptomatic treatment [1]. 
Over-represented in this group are patients bearing 
mutations/deletion of the TP53 gene [2]. Moreover, a 
high-risk CLL patient fraction was confirmed to carry 
mutations/deletion of other genes, such as NOTCH1, 
BIRC3, or SF3B1 [3–7]. 
For years, the standard therapy was based on the 
use of alkylating agents, with negligible (if any) effects 
on the natural history of CLL. The introduction of 
fludarabine signified an important breakthrough in 
CLL therapy. The use of monoclonal antibodies (anti- 
CD20, anti-CD52, etc.) opened a new perspective for 
overcoming the paradigm of treating only patients 
with minimal complications; alone or in combination 
with chemotherapy, these therapeutics significantly 
increased the overall survival of the patients [8, 9]. 
More recently, inhibitors of B-cell receptor signaling 
showed efficacy in a subset of CLL patients [9–11]. 
Despite the advancements in combined therapy, CLL 
remains an incurable disease in most cases since 
complete molecular remission is unachievable and, as 
a consequence, the disease relapses invariably after 
some months or years. In particular, the small subgroup 
of patients, known as the ultra-high-risk CLL group, 
shows poor response to chemo-immunotherapy and 
a life expectancy of less than 2 to 3 years with con-
ventional regimens [10, 12]. These considerations 
indicate that new therapeutic approaches are needed 
to obtain complete recovery or at least to improve  
the survival of CLL patients. Since most patients are 
old and often have several co-morbidities, any new 
treatment approaches, in addition to higher efficacy, 
must be non-toxic to organs and tissues. The dev-
elopment of nanoparticles made with biodegradable 
biopolymers and loaded with chemotherapeutic agents 
is an attractive method to target neoplastic cells [13–15]. 
In fact, nanoparticles can be designed by attaching 
specific antibodies on their surface, so that they are  
able to recognize tumor-associated antigens and induce 
specific homing on the neoplastic cell surface [16, 17]. 
Therefore, the efficacy of high-dose chemotherapy is 
associated with the specificity and low side-effects of 
antibody-based therapy and the protective nature of 
polymeric encapsulated chemotherapeutics.  
On these principles, we developed biodegradable 
nanoparticles (BNPs) coated with an anti-CD20 
antibody to target neoplastic B-cells, and loaded them 
with hydroxychloroquine (HCQ) and chlorambucil 
(CLB) to specifically kill tumor B-cells [18, 19]. To the 
best of our knowledge, this is the first report of the 
safety and therapeutic effects of targeted nanoparticles 
in a new leukemia xenograft SCID mice model. 
2 Experimental 
2.1 Cells, antibodies, and sera 
The CLL-like cell line MEC1 [20] (kindly provided  
by Prof. Josee Golay), carrying both a TP53 mutation 
(i.e. c.422insC) and the 17p13 deletion, was cultured 
in RPMI-1640 medium (Sigma-Aldrich, Milan, Italy) 
supplemented with 10% fetal bovine serum (FBS; GE 
Healthcare Milan, Italy). Heparinized peripheral blood 
samples were obtained from untreated CLL patients 
at the University Hospital in Trieste (B-cells more 
than 90% of total circulating cells) after obtaining 
written informed consent. The study was approved 
by the IRB of the CRO (IRCCS) of Aviano (IRB-06- 
2010). The mononuclear cell fractions were isolated 
by centrifugation on Ficoll-Hypaque (GE Healthcare) 
density gradients [21]. MEC1 cells were suspended  
in serum-free RPMI-1640 medium and stained with 
VybrantTMDiO cell-labeling solution (GE Healthcare) 
as described previously in Ref. [22]. The anti-CD20 
chimeric antibody Rituximab (Roche, Milan, Italy) 
was derived from the clinic (University of Trieste, Italy). 
The mouse mAb to CD20 and anti-PARP1 antibody 
were purchased from BioLegend (San Diego, CA) 
and Bethyl Laboratories, respectively. For immuno-
phenotypical characterization, anti-human CD5 PE 
(Immunotools, Friesoythe, Germany), anti-human 
CD20 (clone L26, Novacastra), anti-human CD45 APC 
(Invitrogen, Milan, Italy), and anti-human CD19 TC 
(GE Healthcare) mAbs were used. Anti-LC3, anti-- 
tubulin mAbs, and all the secondary antibodies were  
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purchased from Sigma-Aldrich (Milan, Italy) or Aczon 
(Monte San Pietro, Bologna, Italy). Human sera from 
AB Rh+ blood donors (NHS-normal human serum) 
were kindly provided by the Blood Transfusion Center 
(Trieste, Italy) as a source of complement (NHS). 
2.2 BNP preparation 
BNPs were prepared using chemicals of reagent grade 
or above. Polyethylene glycol (PEG) was purchased 
from Nektar, San Carlos, CA; HCQ sulfate and CLB 
were purchased from ACROS (Belgium) and Sigma 
Aldrich (St Louis, MO), respectively. BNPs based on 
carboxylic acid terminated biodegradable polymers 
(PLA-b-PEG-COOH and PCL-COOH) were prepared 
with an average diameter of 250 nm, as measured by 
dynamic light scattering (data not shown) in an under 
class 100 clean room conditions by implementing 
Bio-Target’s technology at LNK Chemsolutions, LLC 
laboratories [19, 23]. All the BNPs (final concentration 
of 900 μg/mL) were resuspended in PBS buffer (pH = 
7.4) with 10% BSA. The BNPs were diluted in serum- 
free RPMI-1640 medium and stained with fluorescein 
isothiocyanate isomer I (Sigma-Aldrich) or FluoroLinkTM 
Cy5.5 Monofunctional Dye (GE Healthcare). 
2.3 Animals 
Female SCID mice (4–6 weeks of age) were provided 
by Charles River (Milan, Italy) and maintained under 
pathogen-free conditions. The animals were pretreated 
with cyclophosphamide (200 mg/kg), inoculated 
subcutaneously with 107 MEC1 cells or intravenously 
with 5 × 105 MEC1 cells after 24 h, and examined twice 
weekly up to 125 days. C57/BL mice were obtained 
from the animal house of the University of Trieste. 
All the experimental procedures involving animals 
were performed in compliance with the guidelines of 
the European and the Italian laws and were approved 
by the Italian Ministry of Health as well as by the 
Administration of the University Animal House (Prot. 
42/2012). 
2.4 Cytometric analysis 
The binding of the BNPs was assayed by incubating 
10 μL of BNPs with 5 × 105 MEC1 cells for 1 h at 37 °C. 
MEC1 localization in mouse blood was performed 
using anti-CD45 APC and anti-CD19 TC antibodies at 
28 days after cell injection. For these measurements, 
30,000 events were acquired using FACSCalibur (Becton 
Dickinson, San Jose, CA) flow cytometer and data 
were analyzed using CELLQuest software (Becton 
Dickinson) [24].  
2.5 Transmission electron microscopic analysis 
Samples were fixed for 1 h in a solution of 2% 
glutaraldehyde (Serva, Heidelberg, Germany) in 0.1 M 
cacodylate buffer (pH = 7.3) containing 0.03 M CaCl2, 
rinsed three times (10 min each wash) and postfixed 
in 1% osmium tetroxide for 1 h at 4 °C. Samples were 
then dehydrated in ethanol of increasing gradients to 
100% and embedded in Dow Epoxy Resin (DER 332; 
Unione Chimica Europea, Milan, Italy) and DER732 
(Serva), as previously described by Zabucchi et al. 
[25]. Ultrathin sections were cut using an ultratome 
Leica Ultracut UCT8 (Leica, Wirn, Austria), double 
stained with uranyl acetate and lead citrate and 
observed in a transmission electron microscope (EM 
208, Philips, Eindhoven, The Netherlands). Micrographs 
were taken with a Morada Camera (Olympus, Munster, 
Germany). 
2.6 Cell viability, apoptosis, and autophagy 
To investigate the ability of BNPs to affect cell 
viability, MEC1 cells (2 × 105) were incubated with 
different concentrations of BNPs for 48 h at 37 °C (in a 
humidified 37 °C, 5% CO2 incubator). The amount  
of residual viable cells was determined using the 
MTT assay [26] and the percentage of dead cells was 
calculated as 100× [(test release – spontaneous release)/ 
(total release – spontaneous release)]. Apoptosis of 
the patient’s B cells was measured using FITC-labeled 
recombinant human Annexin V assay (Apoptosis 
detection kit, Immunostep, Spain) according to the 
manufacturer’s instructions. For each measurement, 
30,000 events were acquired using a standard 
FACSCalibur (Becton Dickinson) flow cytometer and 
data were analyzed using CellQuest (Becton Dickinson). 
PARP-1 and LC-3 activation were evaluated by 
immunoblotting to study apoptosis induction and 
autophagy impairment, respectively [27]. 
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2.7 Complement-mediated lysis 
A previously described procedure of complement- 
dependent cytotoxicity (CDC) measurements with 
some modifications was used to evaluate the effect of 
Rituximab® on complement-mediated killing of tumor 
B-cells [28]. The number of residual viable cells was 
estimated using the MTT assay. 
2.8 Blood analysis 
Red and white blood cells and platelets from treated 
and untreated mice were analyzed using ABX Micros 
E660 OT/CT (Horiba ABX Diagnostic, Montpellier, 
France). Other parameters in the animal plasma were 
analyzed using Integrated System Dx 880 (Beckman 
Coulter). 
2.9 Histopathological and immunohistochemical 
analysis 
Liver, spleen, kidney, brain, spinal cord, and bone 
marrow samples from leukemia-bearing mice either 
dead from the tumor or sacrificed at day +120 from cells’ 
injection were obtained at necropsy. For morphologic 
evaluation, the specimens were fixed in 10% buffered- 
formalin solution and embedded in paraffin. Four 
micrometer-thick sections were stained with H&E. 
Four- to six-micrometer thick sections were fixed in 
cold 100% methanol for 15 min. Immunohistochemical 
analysis was performed using the avidin-biotin- 
peroxidase complex method according to standard 
procedures [29], and the slides were examined under 
a Leica DM2000 optical microscope. 
2.10 Statistical analysis 
The data were expressed as mean  SD and analyzed 
for statistical significance by the two-tailed Student’s t 
test to compare two paired groups of data. The Kaplan- 
Meier product-limit method was used to estimate 
survival curves and the log-rank test was adopted to 
compare different groups of mice. 
3 Results and discussion 
3.1 Anti-CD20 BNPs target tumor B-cells  
Current treatment strategies for leukemia involve 
chemotherapy, immunotherapy, bone marrow transplant, 
and several new target therapies. These treatments 
often induce long-term side-effects, resulting in 
impairment of vital physiological functions among the 
survivors. This is particularly true for elderly/unhealthy 
CLL patients. While current treatment approaches 
have greatly improved the prognosis for survival, some 
patients remain refractive to current therapeutic 
regimens. Hence, in addition to reducing the long- 
term residual side-effects of therapeutics for all leukemia 
patients, there is an urgent need for novel therapeutic 
strategies for difficult-to-treat leukemia cases. Due to 
the cytotoxicity of drugs, the major challenge currently 
is to deliver the therapeutic agent to neoplastic cells 
while preserving the viability of non-malignant cells. 
Research on the use of nanoparticles as drug carriers 
has advanced to focus on assessing the safety and 
efficacy of such drug delivery systems. In this study, 
four different types of polymeric nanoparticles, BNP0, 
BNP1, BNP2, and BNP3, were prepared as in Fig. S1 
(in the Electronic Supplementary Material (ESM)) and 
were characterized as previously described in Ref. [19]. 
The BNP0 was prepared only using polymeric carriers 
(PLA-b-PEG-COOH and PCL-COOH); BNP1 was 
prepared by conjugating the anti-CD20 chimeric 
antibody on the surface of BNP0; BNP2 was prepared 
by encapsulating the HCQ sulfate and CLB inside the 
core of BNP1m while BNP3 was prepared by loading 
chemotherapeutic drugs inside BNP0. To characterize 
both untargeted and targeted nanoparticles, trans-
mission electron microscopy (TEM) and dynamic 
light scattering were used. In details, TEM showed 
that untargeted nanoparticles have a core diameter of 
110 ± 40 nm, while anti-CD20-conjugated nanoparticles 
have a core diameter of 90 ± 30 nm. For dynamic light 
scattering analysis, untargeted nanoparticles have an 
hydrodynamic diameter of 190 ± 60 nm, while targeted 
nanoparticles have a diameter of 230 ± 70 nm; moreover, 
the ζ-potential evidenced values of –7.8 ± 0.9 and –6.0 ± 
0.6 mV for untargeted and anti-CD20 conjugated BNPs 
respectively, as previously described in Ref. [19]. 
During the experiments, nanoparticles were stored at 
–20 and +4 °C and then tested. We did not observe 
any significant modification in their morphology and 
their capacity to target and kill tumor B-cells, both  
in vitro and in vivo, which suggested that they could 
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remain stable for almost 1 year after their production. 
To characterize the effect of the BNPs, the CLL-like 
MEC1 cell line was used. It was initially purified from 
a CLL patient [20] and carried a mutation in the TP53 
gene and the 17p13 deletion, as demonstrated by 
direct sequencing and FISH analysis (data not shown). 
Moreover, its immunophenotype was studied by 
cytometric analysis, thus confirming what previously 
reported in literature [30]. In fact, more than 95% of 
the MEC1 cells highly expressed human markers like 
CD20 and CD45, but CD5 expression was not detected 
(Fig. S2 in the ESM). The functional characterization 
of the BNPs was started by evaluating their ability to 
bind to leukemia cells. To this end, BNP0 and BNP1 
were labeled with FITC and added to the MEC1 cells at 
different incubation times. BNP1 could target MEC1 
cells in a dose- and time-dependent manner with a 
maximal uptake after 1 h of incubation and using 
10 μL of the particles. Under these conditions, 74% of 
the cells appeared tagged by BNP1 (Fig. 1(a)). On the 
contrary, BNP0 did not demonstrate specific binding 
after 1 h incubation, suggesting the importance of the 
anti-CD20 antibody in the targeting of the B-cells by 
the BNPs.  
The interaction of the BNPs with MEC1 cells was 
further confirmed by confocal microscopy images by 
incubating cells with BNPs labeled with FAST-DiO 
and Cy5.5, respectively (Fig. S3 in the ESM). Moreover, 
TEM studies were performed to follow the migration 
of the BNPs into tumor B-cells. Two different types of 
BNPs were prepared as shown in Fig. S1 (in the ESM), 
and these were labeled as BNPA and BNPB. BNPA was 
prepared by encapsulating gadopentetate dimeglumine 
(Magnevist H, Bayer HealthCare Pharmaceuticals Inc) 
while BNPB was prepared by conjugating the anti- 
CD20 antibody to the surface of BNPA. By exploiting 
the presence of Gd in the particles, the migration of 
the BNPs was followed by TEM analysis by incubating 
the MEC1 cells with these two different types of BNPs 
(Fig. S1 in the ESM).  
In detail, BNPA was never seen inside the cells (data 
not shown) while images showed the binding of BNPB 
and its interaction with the cell surface. Moreover, 
BNPs were never documented in the nucleus and the 
absence of vesicles surrounding them suggested the 
internalization of the BNPs through a process different  
 
Figure 1 Interaction between tumor B-cells and BNPs.      
(a) Binding of anti-CD20 BNPs to MEC1 cells. MEC1 cells were 
incubated with FITC-labeled BNPs for 1 h at 37 °C and analyzed 
using FACS. FL1-H, green fluorescence, 530/30 nm bandpass 
filter. (b) Internalization of anti-CD20 BNPs to MEC1 cells. 
MEC1 cells were incubated with BNPB for 1 h and analyzed by 
TEM: Ultrastructural appearance of MEC1/BNP1 interaction and 
internalization was documented. Arrows in bII and bIII indicate 
typical cytoplasmic localization of anti-CD20 BNP. Bars represent 
200 nm ((b)I, (b)III), 2 μm ((b)II), and 100 nm ((b)IV). 
from endocytosis (Fig. 1(b)). This data confirmed the 
results previously obtained both in vitro and in vivo 
and demonstrated the importance of a targeting 
agent as an anti-CD20 recombinant antibody on the 
nanoparticle surface [18]. The internalization of BNPs 
outside endosomes has already been demonstrated 
for other tumor B-cell lines incubated with BNPs [18], 
which passed through the membrane without signifi-
cantly disrupting it. 
3.2 BNP2 induces tumor B-cell cytotoxicity  
In this study, CLB and HCQ were loaded inside 
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polymeric nanoparticles because of their synergistic 
effect against cancer B-cells, as we have previously 
described [18]. In particular, CLB is an alkylating agent 
administered orally, whose rate of absorption can vary 
significantly from patient to patient, thus causing 
side-effects in some patients [31, 32]. In addition, most 
B-cell malignancies will become resistant to CLB   
at some point, irrespective of whether it is used at 
increasing doses or within more aggressive regimens. 
In resistant situations, it could be important to have a 
therapeutic system for better delivery of high amounts 
of drugs specifically inside malignant B-cells in order 
to circumvent genetically driven mechanisms of tumor 
resistance. The combination of an elevated concentration 
of CLB intracellularly with another kind of cytotoxic 
drug not dependent on surviving genes could not only 
enhance their respective toxic activities, but perhaps 
make a resistant leukemia cell sensitive again. HCQ 
has demonstrated an interesting cytotoxic effect 
depending on its capacity to block autophagosomes/ 
lysosome fusion. Its anti-neoplastic properties in vitro 
depend on its concentration; however, this property 
is unobtainable in vivo by the usual oral administration 
route [33–36]. The synergistic effect of HCQ and CLB 
was previously described by our group [18] and it 
could be important, especially for CLL patients in an 
already resistant disease state, or in those with poor 
prognostic biological characteristics. These drugs 
together could cause high cytotoxic effects by mainly 
inducing autophagy and apoptosis [18]. In order to 
evaluate the cytotoxic effect of BNPs, MEC1 cells were 
incubated with different amounts of BNP0, BNP1, 
BNP2, and BNP3 for 48 h and the residual viable cells 
were measured. Particles loaded with chemothera-
peutic drugs, such as BNP2 and BNP3, could induce 
cytotoxicity in a dose-dependent manner while empty 
particles, such as BNP1, were almost ineffective. 
Furthermore, 2 μL of BNP2 or BNP3 was sufficient 
to kill more than 85% of the MEC1 cells, suggesting 
that the chemotherapeutic drugs maintained their 
cytotoxic properties even after encapsulation inside 
the nanoparticles. On the contrary, treatment with 
BNP1 killed less than 20% of the cells in this in vitro test, 
showing that this approach had good safety (Fig. 2(a)). 
The cytotoxicity is due to the pro-apoptotic effect   
of the chemotherapeutic drugs. Forty-eight hours of  
 
 
Figure 2 In vitro characterization of the cytotoxic effect of BNP2. 
MEC1 cells (a) were incubated with 0.5, 1, and 2 μL of BNPs or 
HCQ+CLB for 48 h at 37 °C and residual viable cells were 
measured. Data are expressed as mean  SD. (b) MEC1 cells 
were incubated with 1 μL of BNPs for only 16 h at 37 °C and 
apoptotic cells were analyzed using AnnexinV/7AAD test. (c) 
Western blot analysis of activated PARP-1 and LC3 accumulation 
from cell lysates obtained from MEC1 cells incubated with 1: 
saline; 2: 2 μL of BNP1; 3: 0.5 μL of BNP2; 4: 2 μL of BNP2. 
incubation of the cells and particles loaded with 
chemotherapeutic drugs resulted in a high percentage 
of cell destruction, avoiding any possible molecular 
studies. Thus, only 16-h incubations were performed 
to further study apoptosis induction and autophagy 
impairment. In this setting, more than 20% of the 
tumor cells (2 × 105) incubated with 2 L of BNP2 showed 
an apoptotic profile in an AnnexinV/7AAD test 
(Fig. 2(b)). To confirm apoptosis, the poly-(ADP-ribose) 
polymerase (PARP-1) was visualized. The enzyme is 
cleaved from a 113-kDa molecule to fragments of 89 
and 24 kDa during apoptosis. PARP-1 cleavage was 
detected by western blot assay using cell lysates of 
the MEC1 cells incubated with different amounts of 
BNP2 for 16 h. These apoptotic studies revealed that 
BNP2 could induce PARP-1 cleavage, in particular 
using 2 μL of particles with 5 × 105 cells (Fig. 2(c)). 
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The same pattern was found in the study of auto-
phagy, which was impaired by HCQ. This mechanism 
was analyzed by taking into consideration the LC3 
protein, which is processed to a cytosolic version 
(LC3-I, 18-kDa) and then converted to active forms 
commonly used as a marker of autophagosome 
accumulation. The effect of HCQ on MEC1 cells was 
detected by evaluating the increase in the amount of 
LC3-III in lysates of cells incubated for only 16 h with 
0.5 or 2 μL of BNP2 by western blot analysis, also in 
the presence of significant basal level in untreated 
cells (Fig. 2(c)). 
3.3 Comparison between cytotoxic effects of BNP2 
and rituximab  
Rituximab can mainly activate the complement system 
and also induces antibody-dependent cytotoxicity 
(ADCC) but has a very low killing effect due to its 
ability to activate apoptotic pathways. For this reason, 
we compared the killing of MEC1 cells induced by  
a saturating concentration of rituximab through 
complement-dependent killing, or by BNP2 acting 
through apoptosis/authophagy. MEC1 cells were 
analyzed using anti-CD20 mAb, showing high amounts 
of the antigen on the cell surface (mean fluorescence 
intensity-MFI: 784). In this particular setting, rituximab 
killed up to 22% of the MEC1 cells while BNP2 killed 
87% of these leukemia cells (Table 1). The cytotoxic 
effect of BNP2 was evidenced by analyzing purified 
cells from CLL patients. Circulating CLL B-cells 
expressed a lower amount of CD20 on their surface 
compared to the MEC1 cells (MFI: 50.6 vs. 784), as 
observed in cells purified from 31 different untreated 
CLL patients already characterized for the main 
biological prognosticators (Table S1 in the ESM). 
Moreover, as shown in Table 1, the cytotoxic effect of 
rituximab on purified CLL cells ranged between 0 and 
38%, with a median value of 4.2%. On the contrary, 
BNP2 killed up to 84% CLL cells, with a median value 
of 55.1% (BNP2 vs. rituximab: p < 0.00001), and only 1 
out of 31 patients did not respond to the treatment. 
Interestingly, it was also possible to perform these 
studies in whole blood samples, as a predictive 
functional test. Apoptosis was evaluated using the 
Annex V/7AAD test after 16 h of incubation with BNP2. 
In all the samples, more than 98% of the CD5/CD19-  
Table 1 Comparison between the effects of BNP2 and rituximab 
 CD20 (MFI) 
BNP2 
(% of killing) 
RITUXIMAB
(% of killing) 
MEC1 784 86.4 22.0 
Pt 1 73.6 77.4 0.0 
Pt 2 20.2 26.9 1.4 
Pt 3 22.2 81.7 8.9 
Pt 4 76.2 25.4 38.0 
Pt 5 65.9 59.6 9.1 
Pt 6 24.1 0.0 0.0 
Pt 7 38.4 68.4 0.0 
Pt 8 54.8 65.4 1.9 
Pt 9 33.5 54.1 0.0 
Pt 10 38.9 39.4 10.6 
Pt 11 32.7 71.7 3.5 
Pt 12 58.0 58.8 6.2 
Pt 13 35.4 78.8 0.0 
Pt 14 28.0 84.4 0.0 
Pt 15 33.0 64.0 0.0 
Pt 16 25.3 55.1 9.9 
Pt 17 42.4 88.9 31.1 
Pt 18 41.4 44.9 18.0 
Pt 19 64.5 47.9 21.8 
Pt 20 60.5 61.3 2.9 
Pt 21 50.6 10.3 2.7 
Pt 22 75.5 32.6 0.0 
Pt 23 44.5 23.4 0.0 
Pt 24 60.0 29.6 12.6 
Pt 25 53.6 12.9 9.9 
Pt 26 289.1 72.3 9.3 
Pt 27 64.1 28.4 0.0 
Pt 28 40.2 41.0 25.6 
Pt 29 63.9 76.1 5.1 
Pt 30 77.7 63.3 4.2 
Pt 31 82.2 18.2 10.4 
Median (Pt) 50.64 55.1 4.2 
CLL patients (Pt); MFI: mean fluorescence intensity: mean; 
percentage of killing: mean (n = 3). 
positive BNP2-treated cells showed an apoptotic state, 
as against only 11% of the BNP1-treated cells showing 
apoptosis. These results seem to be independent of 
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CD20 expression or of specific biological features; in 
fact, TP53-mutated/deleted or NOTCH1-mutated cells 
of patients who usually have poor response to standard 
therapies (Table S2 in the ESM) were anyway killed 
by BNP2. 
3.4 BNPs show a safe toxicological profile 
Side effects induced by HCQ and CLB have been 
well described in the literature [37, 38] and were also 
evident in our experiments on healthy mice.  
The reduction of side-effects was addressed by 
including CLB+HCQ drugs in BNPs produced from 
biocompatible and biodegradable polymers. The 
development of these nanoparticles with an average 
diameter of 250 nm as drug-delivery agents has several 
advantages, including specific targeting via receptor- 
mediated mechanisms and effective penetration of the 
tumor microenvironment [19]. BNP2 in particular can 
transport and release into tumor B-cells enough amount 
of drugs to kill cancer cells, thus overcoming multidrug 
resistance found in several B-cell disorders [39].  
The toxic effects of the intra-peritoneal injection of 
BNPs were evaluated in groups of five C57/BL mice 
receiving 8 injections of saline, 8 injections of BNP2 
(containing 400 μg of CLB and HCQ), or 4 injections 
of free HCQ+CLB (400 μg each). We have previously 
shown that 8 injections of free drugs killed all the 
animals [18].  
The mice were followed for 28 days. Animal survival, 
total body weight, circulating cells, and several tissue 
markers in the blood were analyzed. All the animals 
survived during the experiment but the free drugs- 
treated mice showed a strong reduction in their body 
weight, with a median of about 20%. Blood samples 
were collected 3 days after the end of the treatments 
in order to evaluate complete blood count, hemoglobin, 
urea, aspartate transaminase (AST), alanine trans-
aminase (ALT), alkaline phosphatase (ALP), lactate- 
dehydrogenase (LDH), creatine phosphokinase (CPK), 
creatinine, and aldolase concentrations (Table 2). We 
did not find any significant differences during any of 
the experiments between the controls and animals 
receiving 8 injections of BNP2; only platelets seemed 
to have increased after the treatments, but remained 
in a physiological range. On the contrary, the animals 
receiving only 4 injections of free HCQ+CLB showed  
Table 2 Toxicological studies 
 Saline BNP2 HCQ/CLB
Body weight 
(% variation) –2.31 –3.29 –20.61
*§ 
WBC (103/mm3) 3.15 ± 1.08 2.13 ± 0.4 0.58 ± 0.33*§
LYMPHOCYTES
(103/mm3) 2.65 ± 1.03 1.60 ± 0.17 0.30 ± 0.18
*§
MONOCYTES 
(103/mm3) 0.18 ± 0.05 0.20 ± 0.17 0.08 ± 0.18
GRANULOCYTES
(103/mm3) 0.33 ± 0.05 0.33 ± 0.06 0.20 ± 0.1
RBC (106/mm3) 7.42 ± 1 5.52 ± 1.47 4.87 ± 0.52*
PLT (103/mm3) 532.25 ± 73.4 688.00 ± 27.22*§ 464.5 ± 93.3
Hemoglobin (g/L) 11 ± 0.6 11 ± 0.4 9.0 ± 1.3*§ 
Urea (mg/dL) 29 ± 5 28 ± 9 28 ± 7 
Creatinine (mg/dL) 0.24 ± 0.06 0.20 ± 0.18 0.14 ± 0.02*
AST (IU/L) 152 ± 52 146 ± 16 182 ± 35 
ALT (IU/L) 26.8 ± 6.0 17.0 ± 5.3 20.3 ± 9.6 
ALP (IU/L) 34.0 ± 10.2 26.7 ± 10.0 18.5 ± 5.8*
LDH (IU/L) 645 ± 82.8 435 ± 98.6 495 ± 41.5*
CPK (IU/L) 2,084 ± 413 1,143 ± 564 1,587 ± 223
Aldolase (IU/L) 9 ± 4 11 ± 2 16 ± 5*§ 
Total body weight, red blood cells (RBC), white blood cells (WBC), 
platelets (PLT), and other plasma parameters from treated and 
untreated mice were compared. *p < 0.05 vs. control; §p < 0.05 
vs. BNP2.  
a reduction in white blood cells, mainly due to the low 
number of circulating lymphocytes, and a significant 
reduction in erythrocytes. 
Simultaneously, we observed reduced concentration 
of hemoglobin, creatinine, ALP, and LDH, with increased 
values of aldolase (Table 2). 
3.5 Development of a disseminated leukemia model 
using MEC1 cells 
A xenograft model of human CLL was previously 
described by Bertilaccio et al. [40], who challenged 
Rag–/–γc–/– mice intravenously or subcutaneously with 
107 MEC1 cells. Unfortunately, we were unable to repeat 
these results in SCID mice; in fact, the intravenous 
injection of 107 cells rapidly killed all the animals by 
causing respiratory problems. On the other hand, 
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subcutaneous cell injection induced only the formation 
of a localized tumor mass at the site of injection without 
colonizing other tissues and causing the death of the 
animals in about 70 days (Fig. 3).  
However, an intravenous injection of only 5 × 105 
MEC1 cells 24 h after a pre-treatment with cyclophos-
phamide (200 mg/kg intraperitoneally), which is 
known to reduce immune effects, in particular via 
NK cells [41, 42], resulted in a diffuse leukemia model 
characterized by the colonization of different organs 
and the blood. In details, the biodistribution pattern of 
the MEC1 cells was evaluated by immunohistochemical 
analysis by staining the tissues with H&E and detecting 
human B cells with an anti-human CD45 antibody 28 
days after MEC1 injection (Fig. 4(a)). MEC1 cells were 
detected in the liver, spleen, kidney, bone marrow, 
spinal cord, and brain. Moreover, the accumulation 
of MEC1 cells in the bloodstream of the mice was 
confirmed by cytometric analysis using anti-human 
CD19 and anti-human CD45 antibodies. The presence 
of human B-cells was detected from the 20th day after 
tumor cell injection (Fig. 4(b)).  
All animals died between 30 and 37 days after tumor 
cell injection (Fig. 3), which confirmed the development 
of a very reproducible and very aggressive leukemia 
human/SCID model, which was useful for the charac-
terization of the therapeutic effect of the targeted 
nanoparticles and also for the development of new 
recombinant antibodies, as already shown for other 
B-cell malignancies [24, 30, 43]. 
3.6 Therapeutic effect of BNP2 in a disseminated 
leukemia human/mouse model 
BNP2 has already shown its ability to target cancer 
B-cells in vivo as well as a potential efficacy in the 
treatment of tumor-bearing mice, as already evidenced 
in other B-cell xenografts [18, 19]. To study the efficacy 
of BNP2 in the treatment of the human/SCID leukemia 
model, MEC1 cells were injected in SCID mice, divided 
into 8 groups of 6–8 animals per group, and followed 
up for 120 days (Fig. 5).  
Group 1 did not receive any treatment; all mice 
died within 30–40 days after tumor cell injection with 
a median survival time of 33.5 days. The therapeutic 
protocol followed our previous data and derived from 
the toxicological profile obtained with free HCQ+CLB.  
 
Figure 3 Development of human/SCID leukemia model. MEC1 
were injected subcutaneously (SC, 107 cells) or intravenously  
(IV, 5 × 105 cells) after cyclophosphamide pre-treatment. Animal 
survival was studied and reported as Kaplan Mayer curves. 
 
Figure 4 Characterization of diffuse leukemia model in SCID 
mice. MEC1 cells (5 × 105) were injected intravenously in SCID 
mice and the distribution of human tumor cells was analyzed after 
28 days by H&E and by exploiting human CD45 (a). Original 
magnification 200×. (b) Human tumor B-cells were also detected 
in circulation by FACS analysis using labeled anti-CD45 and 
anti-CD19 mAbs. 
Thus, group 2 and group 3 both received 80 μL of 
BNP2 (corresponding to 400 μg of each encapsulated 
chemotherapeutic agent targeted via anti-CD20 
antibody) for 8 times in 17 days from the 1st and the 
4th day after MEC1 cell injection, respectively. The 
overall survival of group 2 was 83 days and 3 out of   
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Figure 5 Therapeutic effect of BNPs and HCQ+CLB. SCID mice 
(n = 5–10 per group) received (5 × 106) MEC1 cells intravenously 
and BNP1, BNP2, BNP3, or HCQ+CLB as described in the results; 
animal survival was represented as a Kaplan Mayer curve. 
7 mice were cured at the end of the study (BNP2 × 8 
(day 1) vs. untreated: p < 0.0001; BNP2 × 8 (day 1) vs. 
BNP1 × 8: p < 0.0002; BNP2 × 8 (day 1) vs. BNP3 × 8: p 
< 0.0001; BNP2 × 8 (day 1) vs. HCQ+CLB: p < 0.01; 
BNP2 × 8 (day 1) vs. BNP2 × 4: p < 0.03; BNP2 × 8 (day 1) 
vs. BNP2 × 8 (day 4): not significant). Group 3 received 
the same treatment but starting from day 4, resulting 
in an overall survival of 61 days and 1 out of 7 mice 
was cured (BNP2 × 8 (day 4) vs. untreated: p < 0.0001; 
BNP2 × 8 (day 4) vs. BNP1 × 8: p < 0.0002; BNP2 × 8 
(day 4) vs. BNP3 × 8: p < 0.0001; BNP2 × 8 (day 4) vs. 
HCQ+CLB: p < 0.03; BNP2 × 8 (day 4) vs. BNP2 × 4:  
p < 0.04). These results reveal the ability of BNP2 to 
treat this aggressive human/mouse leukemia model 
with a better outcome when the treatment was started 
at the early stage of the pathology. 
Group 4 received only 4 injections of 80 μL of BNP2 
in 8 days starting from the 4th day after cell injection. 
This treatment improved the overall survival by about 
13.5 days (BNP2 × 4 vs. Untreated: p < 0.002; BNP2 × 
4 vs. HCQ+CLB: p < 0.03).  
Group 5 and group 6 received 8 injections of  
80 μL of BNP1 and BNP3, respectively. Both these 
treatments did not significantly increase the survival 
of the mice, thus demonstrating both the safety of the 
BNPs and the inability of BNP3 to bind to cancer cells 
due to the absence of the anti-CD20 antibody on the 
surface of these particles, as previously demonstrated 
by our group [19]. In vitro, untargeted nanoparticles  
(BNP3) showed cytotoxicity, but their effect was not 
confirmed in vivo. This was probably due to the 
blood flow (for circulating tumor cells) and reduced 
residence time of untargeted nanoparticles in the 
tumor microenvironment. 
Finally, group 7 received 8 injections of HCQ+CLB 
(400 μg each) in 17 days starting from day 1. This 
treatment improved the survival by 2 days and showed 
that BNP2 (groups 2) was more effective than free 
drugs in the treatment of this aggressive human/ 
mouse leukemia model.  
In group 8, 3 animals received 8 injections of free 
drugs but all the mice died due to toxicity in less 
than 20 days, as already described [18].  
4 Conclusions 
In conclusion, the results of the present study revealed 
that anti-CD20 nanoparticles containing HCQ+CLB can 
be effective as a single therapeutic agent in controlling 
aggressive leukemia in the new disseminated model. 
We also provide a rationale for adopting this therapeutic 
approach for the treatment of other B-cell disorders 
with BNP2 or different types of tumors by using other 
monoclonal antibodies to specifically deliver cytotoxic 
agent-loaded nanoparticles in cancer cells. 
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